ProCE Banner Activity

A Look Ahead to SABCS 2022

Conference Coverage
Clinical Thought

Experts highlight key studies to be presented at the 2022 San Antonio Breast Cancer Symposium.

Released: December 05, 2022

Expiration: December 04, 2023

No longer available for credit.

Share

Faculty

Sara A. Hurvitz

Sara A. Hurvitz, MD

Professor of Medicine
Director
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Sara A. Hurvitz, MD

Professor of Medicine
Director
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Sara Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, GlaxoSmithKline, Greenwich Life Sciences, Immunomedics, Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Pieris, PUMA, Radius, Samumed, Sanofi, Seattle genetics/Seagen, Zymeworks.

Contributing Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Dr. Joyce O’Shaughnessy answers healthcare professionals’ questions on biomarkers for neo/adjuvant therapy for early breast cancer, from Clinical Care Options (CCO)